Background
Left ventricular assist devices (LVAD) as a bridge (BTT) to heart transplantation (HTX) may be limited by the formation of anti-HLA antibodies. Whether sensitization occurs with continuous axial flow LVAD implant as assessed by Single Antigen Bead (SAB) assay is unknown.
Methods
Cytotoxic panel reactive antibody (PRA) and SAB assays were analyzed in HTX recipients undergoing LVAD implant as a BTT. Sensitization was defined as peak anti-HLA antibody values of >2000 mean fluorescent intensity as these values have been found to correlate with flow cytometric crossmatch results.
Results
LVADs were implanted as BTT in 30 patients. There were 7% (2/30) of patients prior to and no patients after LVAD implant with PRA >10%. However, 20% (6/30) of patients prior to and 53% (16/30) after LVAD were sensitized as measured by SAB (p=0.024). At HTX, 47% (14/30) of patients remained sensitized. A positive virtual crossmatch was observed in 28% (4/14) of the sensitized patients at HTX. There was no difference between the sensitized and non-sensitized groups (p>0.4 for all) in usage of blood products (64 11 vs. 63 39 units), time to HTX (286 63 vs. 257 48 days) and 1 year after HTX, there were no differences in rejection (total rejection score 0.30 vs. 0.37) and survival (93% vs. 88%).
Conclusion
Allosensitization after LVAD is common despite cytotoxic PRA being negative. One year after HTX, this sensitization does not translate into increased acute cellular or antibody mediated rejection or reduced survival.
Background
Acute allograft dysfunction (AAD) is an important cause of morbidity among heart transplant recipients. The role of donor specific antibodies (DSA) in AAD, with the increasing use of Single Antigen Bead (SAB) assays that have improved the ability to detect DSA, remains unclear.
Methods
We retrospectively reviewed 329 heart transplant recipients followed at our institution. AAD was defined as an acute decline in left ventricular ejection fraction to <50% and a decrement of ≥10% compared to baseline in the absence of cellular rejection. AAD patients were compared with matched 30 heart transplant controls.
Results
There were 10 (3%) patients with AAD, 4 (40%) had DSA detectable by SAB assay compared to 16 (53%) controls (p=0.43). Peak DSA mean fluorescent intensity levels (MFI) were significantly higher at baseline (class I and class II) in AAD compared to controls. DSA MFI values increased at the time of AAD and returned to baseline values in follow-up for these AAD patients (p<0.05), but remained unchanged over time for controls. Six (60%) patients and 1 (3%) control had antibody-mediated rejection (AMR) by endomyocardial biopsy (p<0.01). There were 4 (40%) AAD patients with no DSA or AMR.
Conclusions
AAD after heart transplant is a heterogeneous process characterized by: 1) AMR and DSA, 2) AMR but no DSA, and 3) No AMR or DSA. The presence of DSA is not associated with AAD but quantity assessed by MFI levels may play a role.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.